Table 1

Baseline characteristics of primary pulmonary hypertension patients receiving combination treatment

Patients n20
Females/males n14/6
Age yrs46±10
NYHAFC III/IV n17/3
PFO present/absent n8/12
Time since diagnosis months23±18
Prostanoid treatment duration months16±13
Prostanoid dose# µg·day−1
 Iloprost (aerosolised)30
 Beraprost240
Haemodynamics
Pra mmHg6±5
Mean Ppa mmHg55±11
CI L·min−1·m−21.9±0.4
PVR dyn·s·cm−51147±320
SV mL42±10
Pa,O2 torr67±12
Sv,O2 %59±7
  • Data are presented as mean±sd or absolute numbers unless otherwise indicated

  • NYHAFC: New York Heart Association Functional Class

  • PFO: persistent foramen ovale

  • Pra: right atrial pressure

  • Ppa: mean pulmonary arterial pressure

  • CI: cardiac index

  • PVR: pulmonary vascular resistance

  • SV: stroke volume

  • Pa,O2: arterial oxygen tension

  • Sv,O2: venous oxygen saturation

  • #: median

  • : dose delivered at mouthpiece. 1 dyn=10−5 N; 1 torr=0.133 kPa